Business
Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with the Cancer Research Institute (CRI) to advance the frontiers of immuno-oncology through high-resolution molecular data and AI. The multi-phase project will combine 10x's Chromium single cell and Xenium spatial platforms with advanced AI to build one of the world's most comprehensive translational and preclinical immuno-oncology datasets, spanning more than 20,000 samples, to reveal
About this update from 10x Genomics, Inc.
[{"type":"text","content":"Multi-phase initiative will generate single cell and spatial data from over 20,000 samples across leading immuno-oncology laboratories to map the immune landscape of cancer and drive the next generation of immunotherapies and vaccine discovery ","length":243,"tagName":"p"},{"type":"text","content":"PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with the Cancer Research Institute (CRI) to advance the frontiers of immuno-oncology through high-resolution molecular data and AI. The multi-phase project will combine 10x's Chromium single cell and Xenium spatial platforms with advanced AI to build one of the world's most comprehensive translational and preclinical immuno-oncology datasets, spanning more than 20,000 samples, to reveal how the immune system recognizes and responds to cancer and to inform smarter treatment and prevention strategies for the future.","length":688,"tagName":"p"},{"type":"image","alt":"10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)","displaySize":"","headline":null,"caption":"10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/0862b7da135f6592c758a7fd225e5c41"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ngkNiIWWETdTothBh84MZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0862b7da135f6592c758a7fd225e5c41","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1700607/10x_Genomics_Logo_V1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The initiative will begin with a pilot phase, supported by leading researchers at some of the world's top immuno-oncology laboratories, including John Wherry, Ph.D. (University of Pennsylvania), Ansuman Satpathy, M.D., Ph.D. (Stanford University) and Andrea Schietinger, Ph.D. (Memorial Sloan Kettering Cancer Center). Together, they intend to generate approximately 3,000 samples and analyze them using 10x's Chromium and Xenium platforms, which were selected for this project because they enable generation of large-scale, high-quality datasets with the resolution, consistency and throughput required for AI-driven immuno-oncology ...